China Market Opportunities for International Pharmas
China’s pharmaceutical market presents an immense opportunity for pharmaceutical companies from home and abroad. With a vast population, significant unmet clinical needs, and a rapidly improving regulatory and market access environment, international pharmas have strategically expanded to China to invest in this dynamic market. Over the past four decades, these companies have made substantial investments, introduced hundreds of innovative medicines, and played a pivotal role in advancing the Chinese pharmaceutical industry.
This L.E.K. Special Report explores the strategic opportunities available in China for international pharmas. It explores the changing landscape of the pharmaceutical market, examining how MNCs (Multinational Corporations) have adapted to the “new normal”, fueled innovation, and embraced digital transformation. Additionally, the report sheds light on China’s increasing contributions to global innovation, offering a compelling reason for international pharmas to explore partnerships and collaborations in the country.
The report, ‘China Market Opportunities for International Pharmas’ is written by Justin Wang, Partner at L.E.K. Consulting, China. It is an extract from the book ‘Life Sciences Unicorns: From a China Investment Perspective’ written by Mr. Da Liu and published by The Commercial Press (Singapore) Limited in June 2023.
Comments
Post a Comment